Kymera Therapeutics, Inc. (KYMR)
119.21
+0.40
(+0.34%)
USD |
NASDAQ |
Sep 01, 16:00
119.21
0.00 (0.00%)
After-Hours: 20:00
Kymera Therapeutics Total Long Term Debt (Quarterly) : 66.44M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 66.44M |
| March 31, 2026 | 68.44M |
| December 31, 2025 | 70.31M |
| September 30, 2025 | 72.14M |
| June 30, 2025 | 73.95M |
| March 31, 2025 | 74.65M |
| December 31, 2024 | 76.17M |
| September 30, 2024 | 76.72M |
| June 30, 2024 | 76.76M |
| March 31, 2024 | 78.26M |
| December 31, 2023 | 79.61M |
| September 30, 2023 | 78.26M |
| June 30, 2023 | 72.50M |
| March 31, 2023 | 66.20M |
| Date | Value |
|---|---|
| December 31, 2022 | 14.80M |
| September 30, 2022 | 14.22M |
| June 30, 2022 | 14.79M |
| March 31, 2022 | 14.99M |
| December 31, 2021 | 15.50M |
| September 30, 2021 | 16.00M |
| June 30, 2021 | 15.88M |
| March 31, 2021 | 15.06M |
| December 31, 2020 | 15.42M |
| September 30, 2020 | 15.77M |
| June 30, 2020 | 16.07M |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 18.50M |
| September 30, 2019 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 1.371B |
| Oncolytics Biotech, Inc. | 0.31M |
| Sangamo Therapeutics, Inc. | 19.33M |
| Sarepta Therapeutics, Inc. | 1.046B |
| Anixa Biosciences, Inc. | 0.14M |